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Abstract Varicella zoster virus (VZV) infection has been
implicated in multiple sclerosis (MS), but direct causal in-
volvement has been disputed. Nevertheless, knowledge of
VZV exposure is important, given the risk of serious com-
plications of first exposure while undergoing immunosup-
pressive treatment, in particular with fingolimod. We dis-
tributed questionnaires to MS clinic patients, requesting
information about history of chickenpox, sibling/house-
hold/occupational exposure, history of zoster (shingles),
and disease-modifying treatment. A random, proportionally
representative sample of 51 patients that included patients
with positive, negative, and unknown chickenpox history
were selected for determination of VZV IgG by ELISA. Of
1206 distributed questionnaires, 605 were returned (50%
response rate). Of these, 86% reported history of
chickenpox, 5.6% gave negative history, and 8.5% did not
know. Of 594 who answered the zoster question, 78% gave
a negative response, 4% did not know, and 104 (17%) an-
swered yes. Of these, 83 reported 1 episode; 12 had 2; 5 had
3; and 1 each reported 5, 6, and 15 episodes. Of 51 patients
tested for VZV IgG (44 Byes,^ 4 Bno,^ and 3 BI don’t know^
answers to the question of whether they had chickenpox),
48 were seropositive; the 3 seronegative all had reported
having had chickenpox. The high rate of MS patients
reporting prior chickenpox infection is comparable with
previous reports. A substantial proportion of MS patients,
estimated to be higher than an age-matched general popu-
lation, report single or multiple episodes of zoster. These
data are useful for consideration of immunosuppressive
treatments and/or VZV and zoster vaccination.
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Introduction
Multiple sclerosis (MS) is an immune-mediated inflammatory
disease of the central nervous system (CNS) characterized
pathologically by inflammation, demyelination, axonal loss,
and gliosis, and clinically by a variety of neurological deficits.
The initial clinical course is most frequently relapsing and
remitting (relapsing remitting, RRMS) often followed by a
secondary progressive course (SPMS) and less commonly
(10–15%) showing a progressive deterioration from the onset,
in the form of primary progressive MS (PPMS) (Compston
and Coles 2008).
The cause of MS is unknown but recent studies point to a
multifactorial etiology in which a combination of genetic pre-
disposition (in particular, related to polymorphisms in genes
of the immune response) (Sawcer 2011) and environmental
factors (Ascherio 2013) leads to the disease.
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Of the environmental factors, viruses have been signifi-
cantly implicated in the pathogenesis of MS. The
Herpesviridae family, which includes herpes simplex virus
(HSV), varicella zoster virus (VZV), human herpes virus-6
(HHV-6), cytomegalovirus (CMV), and in particular
Epstein-Barr virus (EBV), have all been associated with MS
(Ascherio 2013).
VZV is a neurotropic double-stranded DNA herpesvirus
with ubiquitous and practically universal distribution.
Primary infection with VZV results in chickenpox which is a
highly contagious infection usually in children. Following
this, VZVremains latent within the dorsal root or cranial nerve
ganglia. Reactivation of VZV manifests as herpes zoster (HZ,
zoster or shingles), consisting of skin eruptions in 1–3 adja-
cent dermatomes. HZ occurs in about 1% of the general pop-
ulation but is more common in elderly and immunosuppressed
individuals (Kleinschmidt-DeMasters and Gilden 2001).
CNS complications of chickenpox are rare and include
cerebellitis, meningitis, myelitis, and Reye’s syndrome. HZ
can be complicated by post-herpetic neuralgia and vasculop-
athy (Gilden 2004).
Recently, an association between VZV/HZ and giant cell
arteritis (Gilden and Nagel 2016) and stroke has been reported
(Breuer et al. 2014).
VZV has long been considered as a potential etiologic
agent in MS, but comprehensive systematic reviews have
failed to detect convincing evidence of a causal association
(Marrie and Wolfson 2001). Although some studies
showed viral DNA in the cerebrospinal fluid (CSF) of pa-
tients with MS in relapse (Sotelo and Corona 2011; Sotelo
et al. 2007, 2014), and a possible association with progres-
sive disease (Ordonez et al. 2010), others failed to confirm
these findings. One relevant case report of detection of viral
DNA in CSF during brainstem relapse suggests that the
underlying mechanisms may be sensory neuronal death
with release of latent virus rather than reactivation of infec-
tion (Torkildsen et al. 2016).
Nevertheless, studies have shown higher prevalence of
VZV seropositivity in patients with MS compared to the
general population (Ross 1998; Ross et al. 1999). The an-
tibody titers against VZV tend to be higher in MS patients
(Ito et al. 1975). Another indicator of exposure and higher
reactivity to VZV in MS is the higher frequency of the MRZ
reaction (CSF antibodies against measles, rubella, and
VZV) which has diagnostic value in MS (Reiber et al.
1998) and prognostic value for conversion of clinically iso-
lated syndrome (a single attack of demyelination) to clini-
cally definite MS (Brettschneider et al. 2009).
These findings are important in the current context of MS
treatment. A number of new immunomodulatory and immu-
nosuppressive treatments have become available for MS.
Although exposure to VZV is detected by the presence of
antibodies, the long-lasting immunity to the virus is primarily
T cell mediated (Arvin 2008). Therefore, treatments targeting
T cells have the potential to diminish the immune responses to
VZV. In the case of primary infection, this could be general-
ized, severe, and even fatal, and the secondary infection could
also be more frequent and severe.
The MS disease-modifying drug that has been most com-
monly associated with VZV/HZ infection is fingolimod
(Arvin et al. 2015). This is a sphingosine-1 phosphate receptor
modulator that acts by inhibiting the migration of CCR7+
lymphocytes from the lymphoid organs, thus depleting naïve
and central memory T cells, but less so the effector memory T
cells, from circulation, and thereby reducing immune
surveillance.
Fingolimod has received special interest because it has
been associated with severe VZV infection, both primary
and reactivation, including two fatal cases (Bourdette and
Gilden 2012). Therefore, vaccination is performed in people
who are seronegative for VZV (Singer 2013). However, in-
creased rates of VZV/HZ infections have also been reported in
MS patients receiving other immunosuppressive drugs, in-
cluding the anti-integrin VLA-4 monoclonal antibody
natalizumab, which blocks activated T cell migration into
the CNS (Kohlmann et al. 2015), and the anti-CD52 mono-
clonal antibody alemtuzumab, a T cell- and B cell-depleting
antibody (Venkatachalapathy et al. 2007). It appears in fact
that the reporting of VZV infections in the post-marketing
setting is disproportionate for fingolimod compared to the
other disease-modifying treatments, and that the real frequen-
cies may be comparable (Arvin et al. 2015).
Given that the use of new generation disease-modifying
treatment is rapidly growing and that these treatments are
known or likely to affect immune surveillance and re-
sponses against VZV, it is important to know the preva-
lence of a history of VZV exposure, as a primary infection
(i.e., a history of chickenpox) or as a reactivation (zoster)
in MS patients.
We performed a questionnaire-based survey of a large MS
clinic in a tertiary care center to assess the frequency with
which MS patients reported a history of chickenpox and of
zoster.
We also performed a serological validation sub-study to
determine the VZV seropositivity of a proportional sample
of the patients who answered Byes,^ Bno,^ or BI don’t know^
to the question whether they had chickenpox.
Method
Patient population and questionnaire
A detailed questionnaire containing questions on the previous
history of chickenpox and zoster was distributed to 1206 ran-
domly selected clinically definiteMS patients registered in the
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Nottingham University Hospital MS clinics, between April
2013 and September 2015. Patients were asked whether they
had ever had chickenpox (yes, no, I don’t know), any episodes
of zoster (Once, More than once, None, I don’t know), age at
the chickenpox/zoster, number of shingles episodes, any his-
tory of vaccinations for chickenpox/zoster, sex, date of birth,
the current MS treatment, and MS phenotype. The question-
naire also included a question on whether the participants
were willing to provide a serum sample for an antibody test
to determine prior exposure to VZV. The questionnaire was
distributed by post or in MS outpatient clinics. For the postal
questionnaires, the participants who did not respond were sent
one final reminder at least 3 months after the first
questionnaire.
Serological validation
Form the returned questionnaire, a random sample,
predetermined to represent ~ 10% of responses and to reflect
roughly the proportions of Byes,^ Bno,^ BI don’t know^ re-
sponses, was recruited for providing a serum sample.
Sera were separated from blood and kept frozen at − 80 °C
until they were thawed for use.
IgG antibodies against VZV were detected using a chemi-
luminescent assay (CLIA) on a Liaison® device (DiaSorin,
Saluggia, Italy). Results higher than 150 mIU/ml are consid-
ered positive.
The study was approved by the Research Ethics Committee
NRES East Midlands-Northampton (Project ref. 11/EM/0215
Epidemiology of varicella zoster infection in patients with
multiple sclerosis).
Statistical analysis
The data were summarized using mean and standard devia-
tions (SD) for normally distributed data, and median and in-
terquartile (IQR) range for skewed data. We used t test for
comparisons of means andMann–Whitney test to test equality
of medians. Statistical analyses were performed using Stata
13.1 (StataCorp. 2009. Stata Statistical Software: Release
13. College Station, TX: StataCorp LP).
Results
Demographics and clinical features of MS
in the respondents
By September 2015, 605 patients returned the questionnaire,
representing a 50% response rate.
Of the respondents, 68% of the patients were female (con-
sistent with the gender distribution in our whole MS clinic
population) (Manouchehrinia et al. 2013) (Table 1).
The mean age was 53 (± 11) years at the time of study.
49.2% of the patients reported that they had relapsing remit-
ting (RR) MS, 32.4% reported secondary progressive (SP)
MS, 8.7% reported primary progressive (PP), and 9.5% were
not aware of their MS phenotype. The mean disease duration
was 19 (± 10) years.
At the time of completion of the questionnaire, 44.7% of
the patients were not receiving any MS-specific disease-mod-
ifying treatments; 18.5% of the respondents were on inter-
ferons followed by 11.1% using glatiramer acetate.
Prevalence of varicella primary infection (chickenpox)
The majority of the patients (86%, n = 518) reported a positive
history of chickenpox. Thirty-four patients (5.6%) reported
that they had no history of chickenpox, and 51 patients
Table 1 Demographic characteristics and VZV history of respondents
Age at last clinic visit (mean (SD)) 53 (11)
Female (%) 73.2
Clinical phenotype at last clinic visit (%)
Relapsing remitting 49.3
Primary progressive 8.7
Secondary progressive 32.4
Unknown 9.6
Disease duration, years (mean (SD)) 19.3 (10.7)
Chickenpox
Ever had chickenpox (%)
No 5.6
Yes 85.9
Don’t know 8.4
Age at the time of chickenpox (mean (SD)) 10 (8)
Interval between chickenpox and onset
of MS (mean (SD), range)
25 (13),
− 39 to 60
Job that may involve contact with chickenpox (%)
Never 51.6
Past 35.9
Now 12.5
Zoster (shingles)
Ever had zoster (%)
No 78
Once 14
More than once 3.5
Don’t know 4.4
Age at the time of first zoster (mean (SD)) 37 (16)
Timing of first zoster episode (%)
Before MS onset 56
- Median time to MS (years) 8
After MS onset 42
- Median time after MS (years) 15
Don’t know 2
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(8.4%) did not know if they ever had chickenpox. The average
age at the time of chickenpox was 10 (± 8, n = 476 respon-
dents) (Table 1) This corresponds to 84% of patients reporting
having had chickenpox by the age of 15, compared to 89% in
England and Wales becoming seropositive in a sero-
epidemiological study (Nardone et al. 2007).
The average interval between the chickenpox infection and
the onset of MSwas 25 years, with a wide range between − 39
and 60 years.
Of 51 patients tested for VZV IgG (44 Byes,^ 4 Bno,^ and 3
BI don’t know^ answers to the question of whether they had
chickenpox), 48 were seropositive, including all the patients
with Bno^ or BI don’t know^ answers; the 3 seronegative all
had reported a positive history of chickenpox. The results
were discussed with the patients, who did not wish further
investigations. They were advised to discuss vaccination with
their general practitioners.
In the majority of the patients (96%, 497 respondents), the
chickenpox episode occurred before the onset of MS. In 17
participants (3%), the episode of chickenpox occurred after
the onset of MS. Five participants (1%) could not give the
timing of the chickenpox relative to the onset of their MS.
A total of 72 patients (12.5%) reported currently having a
job that may involve contact with people with chickenpox.
Two hundred six participants (36%) reported having such a
job in the past. Two hundred ninety-six (51.5%) reported nev-
er having had a job that may have involved contact with peo-
ple with chickenpox.
Prevalence of zoster infection
Of the 594 respondents who answered the zoster history ques-
tion, 78% gave a negative response, 4% responded they did
not know, and 104 patients (17%) gave a positive history of at
least one episode of zoster. Of these 104 patients, 83 had 1
episode; 12 had 2; 5 had 3; and 1 each 5, 6, and 15 reported,
though not always confirmed episodes (the number of epi-
sodes in one patient was missing). The average age at the time
of first zoster episode was 37 (± 16, n = 97). The second
episode of zoster occurred at the average age of 44 (±11,
n = 14). 56% (n = 57) of the patients had their first episode
of zoster before MS onset and 42% (n = 43) had it after de-
velopingMS. Two patients (2%) answered did not knowwhen
their zoster occurred in relation to their MS onset; and 2 did
not answer the question.
In the 53 patients who had zoster before MS, the median
time to MS onset was 8 years. The median time from MS
onset to the first episode of zoster was 15 years in those who
had zoster after developing MS.
There was no difference in the proportion of males versus
females affected by zoster in this cohort.
The medical records of the respondents with 5 or more
episodes of zoster were reviewed. No specific immunological
or hematological abnormalities and no concomitant infections
were present, and there was no history of propensity to other
infections. The course of MS was relapsing remitting in all of
them. The patient with 15 episodes participated in a placebo-
controlled clinical trial of experimental hookworm infection.
The treatment allocation was not known. She only had 1 ep-
isode during the trial and had no immunological abnormalities
or a worsening of the MS course during the trial. She was on
periodic acyclovir treatment and anti-herpes zoster vaccina-
tion was considered by her general practitioner. Based on the
available history, it remained unclear whether all of the exac-
erbations represented herpes zoster or the more plausible her-
pes simplex infection.
Prior vaccinations
Three hundred eighty-nine patients (65.1%) reported no pre-
vious history of vaccination for chickenpox or shingles. Fifty-
three (8.8%) were previously vaccinated and 155 (26%) did
not know their vaccination history. However, these self-
reported numbers were not confirmed by vaccination records
in the general practitioners’ referral letters of those who re-
ported prior vaccination, suggesting that the question was
misinterpreted.
Discussion
The primary aim of this study was to investigate the preva-
lence of a history of exposure to VZVas primary infection and
of zoster infection in a large and well-characterized MS pop-
ulation. This is, to our knowledge, a novel questionnaire-
based investigation in the contemporary landscape of MS
disease-modifying treatment, where some new immune
response-modifying drugs may lead to serious complications
in unexposed patients, and where immunity to VZV needs to
be tested prior to institution of treatment with these drugs, in
particular fingolimod.
This study was started before fingolimod became routine
treatment in our clinics, and in fact, it was designed in antic-
ipation of the introduction of this drug. It was also initiated
before the newer oral treatments became available, and thus,
the greatest majority of treated patients had first-generation
injectable disease-modifying treatments.
The prevalence of a history of chickenpox, as reported by
the participants, was very high, as expected for the general
population (CDC, Chickenpox information https://www.cdc.
gov/chickenpox/about/). The majority of people who do not
recall a history of chickenpox in fact have had it. In these
cases, it often may have been mild, with only a few vesicles
that may not have been observed, and in particular, if a sibling
living in the household was affected at the same time, it is very
likely that infection was present. Consistent with this, all 7
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patients who responded Bno^ or BI don’t know^ to the question
of whether they had chickenpox were seropositive for VZV,
proving past exposure.
The differences between the percentage of patients reporting
chickenpox by the age of 15 in our study and those reported to
be seropositive by the age of 15 (Nardone et al. 2007) were
relatively small (84 versus 89%, respectively). Whether these
differences suggest older ages at chickenpox are associated
with an increased risk of MS, as is the case with EBV
(Ascherio 2013) needs to be determined in further studies.
With increasing use of fingolimod and other drugs that can
affect immunity to VZV, including natalizumab and
alemtuzumab, the MS-treating clinicians need to remain vig-
ilant to the fact that a minority of people remain unexposed to
VZV past their early childhood years. The fact that 3% of the
respondents had their primary VZV infection after the onset of
their MS emphasizes the need for vigilance. It is, therefore,
important to test VZV status prior to such treatments. This is
particularly important in those with an occupation that may
increase the risk of exposure to the virus, including jobs in
health care or schools.
The prevalence of zoster infection was 17%. Although an
age-matched population consisting of people with noMS and/
or a population with other neurological diseases was not stud-
ied simultaneously, it appears as if the proportion of zoster
infection, in this MS population that is not subject to major
immunosuppressive treatments, is higher than expected in a
matched general population. The prevalence of zoster is rela-
tively high in the general population, to the point that almost 1
in 3 elderly people have zoster, but this prevalence increases
dramatically after the age of 60, whereas the population tested
here has a mean age of 53. Our results are very similar to those
of Ross et al. (1999), in a Canadian MS population of similar
size (n = 633), where a history of zoster was positive in 16.8%
(Ross et al. 1999). The prevalence of zoster in a practice-based
survey used as comparator in that study was 5.4%, and in a
group of patients with other neurological disease, it was 6.8%
(Ross et al. 1999).
We did not find gender differences in the frequency of zos-
ter, contrary to studies which have reported a higher incidence
in females (Fleming et al. 2004). Therefore, the higher frequen-
cy of shingles in our MS population cannot be explained by the
higher proportion of females, suggesting a real difference.
Therefore,MS patients, untreated with immunosuppressive
drugs, seem to have a higher prevalence of zoster than the
general population. This finding needs to be taken into ac-
count in studies aimed at estimating the expected risk of zoster
under specific treatments, as it indicates that a matched MS
population would be a better comparator than a general pop-
ulation. It also suggests that vaccination against herpes zoster
could be considered in people with MS, in particular in those
about to be treated with disease-modifying drugs potentially
affecting VZV responses.
The fact that the majority (56%) of patients with a
history of zoster had their first infection prior to the onset
of their MS, and the relatively short interval (median of
8 years) before MS onset confirms recent findings impli-
cating HZ as a risk factor for MS development and
reactivates some of the hypothesis linking it to MS etiol-
ogy and pathogenesis (Kang et al. 2011). Alternatively, a
history of zoster at a young age may represent a marker of
abnormal immune function likely to predispose to MS. In
addition, one needs to bear in mind that very mild zoster
in children can go unnoticed or undiagnosed.
The negative results of the VZV IgG antibody test in 3
of the 51 tested patients with MS and a clear history of
primary varicella infection can be explained as false neg-
ative results. The protective immunity against VZV is
normally life-long and it is mediated by T cells, while
antibodies are used to test exposure in routine practice
(Arvin 2008). Although the assay used here was reason-
ably sensitive and is reported to be superior to other as-
says (Maple et al. 2009), false negatives are encountered
in our clinical laboratory where confirmatory tests at the
National Reference Laboratory or cell-mediated immunity
assays are performed depending on clinical indication. In
this study, further clinical testing was not deemed clini-
cally necessary in these individuals.
In conclusion, this study provides results of an epide-
miological survey of VZV exposure in an MS clinic pop-
ulation, with useful data on the prevalence of a history of
the primary infection, reactivation in the form of zoster,
and associated demographics. The existence of a minority
of MS patients who have not been exposed to VZV and
who acquire the primary infection after the onset of MS
needs to be taken into account in therapeutic decision-
making processes. The substantial proportion of subjects
who had a history of zoster before the development of MS
suggests the virus as a possible risk factor for MS or
marker of an immune response that predisposes to MS.
Moreover, a history of zoster infection seems to be more
common in people with MS than would be expected in a
general MS population.
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